Corrigendum to: “miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression” (Biomedicine and Pharmacotherapy (2015) 71 (112–118)(S0753332215000438)(10.1016/j.biopha.2015.01.026));MiR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression

Biomedicine and Pharmacotherapy

Volumn 71, Issue , 2015, Pages 112-118

  Wei, Junhua ^a   Qi, Xuchen ^a   Zhan, Qitao ^b   Zhou, Daoyang ^a   Yan, Qingfeng ^c   Wang, Yirong ^a   Mo, Lianjie ^a   Wan, Yingfeng ^a   Xie, Dajiang ^a   Xie, Jixi ^a   Yang, Shuxu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Glioblastoma cells; Leucine rich repeats and immunoglobulin like domains 1 (LRIG1); MiR 20a; Temozolomide

Indexed keywords

LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 1 PROTEIN; MICRORNA 20A; REGULATOR PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN20 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; GENE TARGETING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE, NUDE; MICRORNAS;

EID: 84928951116     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.09.109     Document Type: Erratum

References (33)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Van Meir E.G., Hadjipanayis C.G., Norden A.D., Shu H.K., Wen P.Y., Olson J.J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60:166-193.
3. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Miska E.A. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005, 15:563-568.
6. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11:597-610.
7. Shi L., Chen J., Yang J., Pan T., Zhang S., Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010, 1352:255-264.
8. Ujifuku K., Mitsutake N., Takakura S., Matsuse M., Saenko V., Suzuki K., et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010, 296:241-248.
9. Wong S.T., Zhang X.Q., Zhuang J.T., Chan H.L., Li C.H., Leung G.K. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 2012, 32:2835-2841.
10. Shi L., Zhang S., Feng K., Wu F., Wan Y., Wang Z., et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 2012, 40:119-129.
11. Yang Y.P., Chien Y., Chiou G.Y., Cherng J.Y., Wang M.L., Lo W.L., et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33:1462-1476.
12. Asuthkar S., Velpula K.K., Chetty C., Gorantla B., Rao J.S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3:1439-1454.
13. Weng H., Huang H., Dong B., Zhao P., Zhou H., Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer research 2014, canres:1748.2013.
14. Chai H., Liu M., Tian R., Li X., Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011, 43:217-225.
15. Malzkorn B., Wolter M., Liesenberg F., Grzendowski M., Stuhler K., Meyer H.E., et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2010, 20:539-550.
16. Yao X., Li W., Wang Y., Ding Z., Hou W., Zeng M., et al. [Expression of hsa-miR-20a in human glioma tissues and its effect on the proliferation of human glioma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao 2012, 32:198-201.
17. Wang Z., Wang B., Shi Y., Xu C., Xiao H.L., Ma L.N., et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene 2014.
18. Qi X.C., Xie D.J., Yan Q.F., Wang Y.R., Zhu Y.X., Qian C., et al. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochem Biophys Res Commun 2013, 437:565-572.
19. Mao F., Wang B., Xi G., Sun W., Zhang H., Ye F., et al. Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells. J Huazhong Univ Sci Technolog Med Sci 2012, 32:227-232.
20. Xie R., Yang H., Xiao Q., Mao F., Zhang S., Ye F., et al. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep 2013, 29:177-184.
21. Cao C., Huang X., Han Y., Wan Y., Birnbaumer L., Feng G.S., et al. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. Sci Signal 2009, 2:ra17.
22. Chen M.B., Wu X.Y., Gu J.H., Guo Q.T., Shen W.X., Lu P.H. Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 2011, 60:311-322.
23. Cai M., Han L., Chen R., Ye F., Wang B., Han F., et al. Inhibition of LRIG3 gene expression via RNA interference modulates the proliferation, cell cycle, cell apoptosis, adhesion and invasion of glioblastoma cell (GL15). Cancer Lett 2009, 278:104-112.
24. Li P., Lu X., Wang Y., Sun L., Qian C., Yan W., et al. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 2010, 24:436-443.
25. Wang J., Sai K., Chen F.R., Chen Z.P. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 2013, 72:147-158.
26. Chen L., Zhang J., Han L., Zhang A., Zhang C., Zheng Y., et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep 2012, 27:854-860.
27. Tang H., Bian Y., Tu C., Wang Z., Yu Z., Liu Q., et al. The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets 2013, 13:221-231.
28. Munoz J.L., Bliss S.A., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids 2013, 2:e126.
29. Comincini S., Allavena G., Palumbo S., Morini M., Durando F., Angeletti F., et al. microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther 2013, 14:574-586.
30. Min H., Yoon S. Got target?: computational methods for microRNA target prediction and their extension. Exp Mol Med 2010, 42:233-244.
31. Tang J.B., Svilar D., Trivedi R.N., Wang X.H., Goellner E.M., Moore B., et al. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 2011, 13:471-486.
32. Agnihotri S., Gajadhar A.S., Ternamian C., Gorlia T., Diefes K.L., Mischel P.S., et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 2012, 122:253-266.
33. Gaspar N., Marshall L., Perryman L., Bax D.A., Little S.E., Viana-Pereira M., et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010, 70:9243-9252.